# NRG-GU006 (NCT03371719)

> Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial

No report yet. It can be ordered.

- Drugs tested: apalutamide
- Indication: recurrent prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03371719
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: NRG Oncology
- Conditions: Recurrent Prostate Carcinoma; Stage III Prostate Adenocarcinoma AJCC v7; Stage IV Prostate Adenocarcinoma AJCC v7
- Interventions: Apalutamide; External Beam Radiation Therapy; Placebo Administration
- Enrollment: 298
- Primary outcome: Percentage of Participants Alive Without Biochemical Progression (Biochemical Progression-free Survival)

## Indexed commentary on NRG-GU006 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 41 posts on X
- 2 YouTube videos
- 2 podcast episodes

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nrg-gu006-nct03371719

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03371719", "email": "<work email>"}; the inbox owner confirms by the emailed link.